, and the 36-month beta value for BCRX is at 1.97. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 0 rating it as “overweight,” 5 as “hold,” and 0 as “sell.”
The average price suggested by analysts for BCRX is $14.95, which is $6.38 above the current market price. The public float for BCRX is 184.56M, and currently, shorts hold a 16.91% of that float. The average trading volume for BCRX on May 24, 2023 was 2.89M shares.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
BCRX) stock’s latest price update
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX)’s stock price has plunge by 2.33relation to previous closing price of 8.57. Nevertheless, the company has seen a 3.66% surge in its stock price over the last five trading sessions. Barron’s reported on 09/27/21 that Medicine’s Golden Age Is Dawning. 10 Stocks to Play the Latest Innovations.
BCRX’s Market Performance
BioCryst Pharmaceuticals Inc. (BCRX) has experienced a 3.66% rise in stock performance for the past week, with a 15.24% rise in the past month, and a -10.24% drop in the past quarter. The volatility ratio for the week is 2.88%, and the volatility levels for the past 30 days are at 3.87% for BCRX. The simple moving average for the last 20 days is 7.02% for BCRX stock, with a simple moving average of -20.89% for the last 200 days.
BCRX Trading at 7.07% from the 50-Day Moving Average
After a stumble in the market that brought BCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.16% of loss for the given period.
Volatility was left at 3.87%, however, over the last 30 days, the volatility rate increased by 2.88%, as shares surge +17.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.54% upper at present.
During the last 5 trading sessions, BCRX rose by +3.66%, which changed the moving average for the period of 200-days by -37.58% in comparison to the 20-day moving average, which settled at $8.26. In addition, BioCryst Pharmaceuticals Inc. saw -23.61% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCRX starting from Thackray Helen M., who sale 7,000 shares at the price of $8.29 back on Apr 03. After this action, Thackray Helen M. now owns 207,275 shares of BioCryst Pharmaceuticals Inc., valued at $58,030 using the latest closing price.
Stonehouse Jon P, the President & CEO of BioCryst Pharmaceuticals Inc., sale 100,000 shares at $10.38 during a trade that took place back on Feb 01, which means that Stonehouse Jon P is holding 1,008,739 shares at $1,038,000 based on the most recent closing price.
Stock Fundamentals for BCRX
Current profitability levels for the company are sitting at:
- -54.81 for the present operating margin
- +97.03 for the gross margin
The net margin for BioCryst Pharmaceuticals Inc. stands at -91.24. The total capital return value is set at -31.82, while invested capital returns managed to touch -53.21. Equity return is now at value 83.90, with -42.50 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 6.68, with the company’s debt to enterprise value settled at 0.30. The receivables turnover for the company is 6.77 and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.90.
Conclusion
In conclusion, BioCryst Pharmaceuticals Inc. (BCRX) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
